WNW - PLTR BLUE among premarket losers
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21% as FQ3 trails estimates.China Liberal Education (CLEU) -14%.Bio-Path Holdings (BPTH) -14% after pricing stock offering.Wunong Net Technology (WNW) -10%.Nano Dimension (NNDM) -9% after pricing stock offering.Washington Prime Group (WPG) -8%.Equillium (EQ) -8%.Palantir Technologies (PLTR) -7% on Q4 earnings.Gilat Satellite Networks (GILT) -8% on Q4 earnings.Can-Fite BioPharma (CANF) -7%.iFresh (IFMK) -6%.Galmed Pharmaceuticals (GLMD) -7% on launch of share offering.Muscle Maker (GRIL) -7%.Monopar Therapeutics (MNPR) -7%.Lianluo Smart (LLIT) -7%.Orchard Therapeutics (ORTX) -7%.SemiLEDs (LEDS) -6%.Galapagos (GLPG) -6%.SunLink Health Systems (SSY) -6%.Baudax Bio (BXRX) -6% on FY earnings.Stealth BioTherapeutics (MITO) -5%.
For further details see:
PLTR, BLUE among premarket losers